RITA - A small-molecular anticancer drug that targets p53

Expert Opinion on Investigational Drugs

Volumn 14, Issue 6, 2005, Pages 739-742

  Doggrell, Sheila A ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b AUCKLAND UNIVERSITY OF TECHNOLOGY   (New Zealand)

Author keywords

Colon cancer; Immunodeficient mice; NSC 652287; P53; RITA; Tumour cell lines

Indexed keywords

2,5 BIS(5 HYDROXYMETHYL 2 THIENYL)FURAN; ANTINEOPLASTIC AGENT; DOXORUBICIN; FLUOROURACIL; FURAN DERIVATIVE; HUMAN DOUBLE MINUTE 2 PROTEIN; NSC 652287; NUTLIN 3; PROTEIN; PROTEIN INHIBITOR; PROTEIN P53; UNCLASSIFIED DRUG; NEW DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COLON CARCINOMA; DRUG TARGETING; FIBROSARCOMA; GENE ACTIVATION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; MOUSE; MOUSE STRAIN; NONHUMAN; OSTEOSARCOMA CELL; TUMOR SUPPRESSOR GENE; WILD TYPE; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECT; METHODOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUGS, INVESTIGATIONAL; FURANS; GENES, P53; HUMANS;

EID: 21244493196     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.6.739     Document Type: Article

References (8)

1. VOGELSTEIN B, LANE D, LEVINE AJ: Surfing the p53 network. Nature (2000) 408:307-310.
2. CHENE P: Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat. Rev. Cancer (2003) 3:102-109.
3. ISSAEVA N, BOZKO P, ENGE M et al.: Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. (2004) 12:1321-1328.
4. RIVERA MI, STINSON SF, VISTICA JT et al.: Selective toxicity of the tricyclic thiophene NSC 652287 in renal carcinoma cell lines. Biochem. Pharmacol. (1999) 57:1283-1295.
5. NIEVES-NEIRA W, RIVERA MI, KOHLHAGEN G et al.: DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells. J. Pharmacol. Exp. Ther. (1999) 56:478-484.
6. ZHAO J, WANG M, CHEN J et al.: The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure. Cancer Lett. (2002) 183:69-77.
7. LAI Z, YANG T, KIM YB et al.: Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors. Proc. Natl. Acad. Sci. (2002) 99:14734-14739.
8. VASSILEV LT, VU BT, GRAVES B et al.: In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 303:844-848.